Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 30, 2025, regarding Flora Growth Corp. (Note: The request metadata listed "Zerostack Corp.", but the filing text identifies the registrant as Flora Growth Corp., trading under symbol FLGC on the NASDAQ Capital Market). The report details the outcomes of the Company's 2025 Annual and Special Meeting of Shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the closing share price of $0.58 on June 30, 2025, which was used as the basis for repricing Stock Appreciation Rights (SARs).
Material Changes and Corporate Actions
- 2022 Incentive Compensation Plan Amendment: Shareholders approved increasing the number of common shares reserved for issuance under the 2022 Plan from 2,500,000 to 4,500,000 shares.
- Stock Appreciation Rights (SAR) Repricing: Shareholders approved repricing outstanding SARs (granted in Dec 2023, Aug 2024, and Dec 2024) to an exercise price of $0.58. Vesting terms were amended to be performance-based, requiring share price increases of 25% increments from the grant date price to vest tranches.
- Share Consolidation Authority: Shareholders granted the Board authority to effect a share consolidation at a ratio between 10:1 and 100:1 within one year, without further shareholder approval.
Shareholder Voting Results and Management Commentary
The following proposals were submitted to a vote at the Annual Meeting:
- Proposal 1 (Election of Directors): Approved. Clifford Starke, Sammy Dorf, Edward Woo, Manfred Leventhal, and Harold Wolkin were elected. Significant "Against" votes were recorded for Clifford Starke (approx. 1.5M) and Harold Wolkin (approx. 265k).
- Proposal 2 (Auditor Reappointment): Approved. Davidson & Company LLP was reappointed.
- Proposal 3 (2022 Plan Amendment): Approved. Shareholders voted to increase the share reserve.
- Proposal 4 (New SAR Grant to Executives): Not Approved. Shareholders rejected the grant of new SARs to the CEO, CFO, and Executive Chairman. Votes Against (7,547,118) significantly exceeded Votes For (1,291,659).
- Proposal 5 (Share Consolidation Authority): Approved. The Board received discretion to consolidate shares.
- Proposal 6 (SAR Repricing): Approved. Shareholders approved the repricing and vesting amendment of existing SARs.
Investor Verification Checklist
- Verify the impact of the rejected Proposal 4 on executive compensation strategy and retention.
- Monitor the Board's exercise of the newly granted authority to consolidate shares (10:1 to 100:1 ratio) within the next 12 months.
- Review the specific vesting milestones for the repriced SARs, which now require significant share price appreciation (up to 225% for some tranches) to vest.
- Assess the level of dissent in the director elections, particularly for Clifford Starke, as an indicator of shareholder sentiment.
- Confirm the total number of shares now available for issuance under the amended 2022 Plan (4,500,000) and its potential dilution effect.